Skip to main content
SpringerLink
Log in

Hepatitis C

Weitere Therapieoption bei HCV-Genotyp-1/-3

  • journal club
  • Published:
Gastro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion“ AWMF-Register-Nr.: 021/012

  2. Kowdley KV et al. Hepatology 2016;64:Suppl1:73

  3. Zeuzem S, Foster GR, Wang S et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 Jan 25;378(4):354–69

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II Universitätsklinikum Freiburg Medizinische Fakultät Albert-Ludwigs-Universität Freiburg, Hugstetter Str 55, 79106, Freiburg, Deutschland

    Rafael Käser

  2. Klinik für Innere Medizin II Universitätsklinikum Freiburg, Medizinische Fakultät, Freiburg, Deutschland

    Robert Thimme (Ärztlicher Direktor)

Authors
  1. Rafael Käser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Thimme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Käser.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Käser, R., Thimme, R. Weitere Therapieoption bei HCV-Genotyp-1/-3. Gastro-News 5, 20–22 (2018). https://doi.org/10.1007/s15036-018-0384-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15036-018-0384-4

Search

Navigation